Cargando…

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). EGFR and HER2 overexpression is associated with aggressive breast cancer with a high risk of disease relapse and death. Although lapatinib targets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oakman, Catherine, Pestrin, Marta, Zafarana, Elena, Cantisani, Egidia, Di Leo, Angelo
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004582/ https://www.ncbi.nlm.nih.gov/pubmed/21188093

Ejemplares similares

Significance of Micrometastases: Circulating Tumor Cells and Disseminated Tumor Cells in Early Breast Cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer
por: Oakman, Catherine, et al.
Publicado: (2009)

The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study
por: Stebbing, Justin, et al.
Publicado: (2013)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
por: Turner, Natalie, et al.
Publicado: (2014)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
por: Maeda, Shingo, et al.
Publicado: (2022)

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005)

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
por: Chew, Helen Kent, et al.
Publicado: (2014)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review
por: Yuan, Ye, et al.
Publicado: (2023)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer
por: De Luca, Francesca, et al.
Publicado: (2016)

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer()()
por: Zhang, Lixin, et al.
Publicado: (2015)

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
por: Hammerman, Ariel, et al.
Publicado: (2015)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
por: Strickley, John D., et al.
Publicado: (2018)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
por: Inoue, Kenichi, et al.
Publicado: (2015)

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
por: Iqbal, S., et al.
Publicado: (2011)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
por: TIAN, XUEFEI, et al.
Publicado: (2016)

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
por: O’Neill, Fiona, et al.
Publicado: (2012)

A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer
por: Nelson, Michael H, et al.
Publicado: (2007)

Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells
por: Ma, S, et al.
Publicado: (2016)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
por: Guérin, Annie, et al.
Publicado: (2014)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1f7d9pq64r53ns4es7vvaujm50